| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 168 | 2024 | 672 | 33.270 |
Why?
|
| Tissue and Organ Procurement | 74 | 2025 | 288 | 18.490 |
Why?
|
| Tissue Donors | 63 | 2025 | 391 | 12.190 |
Why?
|
| Waiting Lists | 63 | 2025 | 237 | 11.930 |
Why?
|
| Kidney Failure, Chronic | 67 | 2024 | 547 | 10.740 |
Why?
|
| Graft Survival | 69 | 2024 | 512 | 8.750 |
Why?
|
| Living Donors | 53 | 2024 | 287 | 6.810 |
Why?
|
| Organ Transplantation | 19 | 2025 | 228 | 6.300 |
Why?
|
| Liver Transplantation | 21 | 2025 | 831 | 5.140 |
Why?
|
| Registries | 66 | 2024 | 1896 | 4.800 |
Why?
|
| Transplant Recipients | 20 | 2024 | 162 | 4.330 |
Why?
|
| Graft Rejection | 36 | 2024 | 598 | 4.180 |
Why?
|
| Renal Dialysis | 36 | 2024 | 423 | 3.850 |
Why?
|
| Lung Transplantation | 8 | 2024 | 289 | 3.620 |
Why?
|
| United States | 125 | 2025 | 13903 | 3.590 |
Why?
|
| Renal Insufficiency, Chronic | 33 | 2023 | 566 | 3.430 |
Why?
|
| Heart Transplantation | 9 | 2024 | 721 | 3.390 |
Why?
|
| Healthcare Disparities | 17 | 2024 | 578 | 3.220 |
Why?
|
| Quality Indicators, Health Care | 9 | 2018 | 298 | 2.970 |
Why?
|
| Transplants | 10 | 2022 | 35 | 2.860 |
Why?
|
| Humans | 341 | 2025 | 129650 | 2.620 |
Why?
|
| Medicare | 15 | 2024 | 720 | 2.490 |
Why?
|
| Kidney | 34 | 2024 | 1385 | 2.470 |
Why?
|
| Middle Aged | 163 | 2024 | 31154 | 2.400 |
Why?
|
| Health Services Accessibility | 17 | 2025 | 902 | 2.400 |
Why?
|
| Adult | 146 | 2024 | 35576 | 2.150 |
Why?
|
| Risk Factors | 78 | 2024 | 9765 | 2.090 |
Why?
|
| Male | 203 | 2024 | 63681 | 2.090 |
Why?
|
| End Stage Liver Disease | 5 | 2024 | 78 | 2.080 |
Why?
|
| Donor Selection | 13 | 2023 | 75 | 2.060 |
Why?
|
| Aged | 124 | 2024 | 22103 | 2.010 |
Why?
|
| Glomerular Filtration Rate | 32 | 2024 | 711 | 1.980 |
Why?
|
| Female | 195 | 2024 | 68776 | 1.840 |
Why?
|
| Delayed Graft Function | 9 | 2024 | 30 | 1.820 |
Why?
|
| Patient Selection | 9 | 2018 | 663 | 1.820 |
Why?
|
| Social Determinants of Health | 5 | 2024 | 221 | 1.790 |
Why?
|
| Treatment Outcome | 64 | 2024 | 10230 | 1.760 |
Why?
|
| Program Evaluation | 8 | 2021 | 875 | 1.670 |
Why?
|
| Retrospective Studies | 79 | 2024 | 14518 | 1.630 |
Why?
|
| Time Factors | 49 | 2024 | 6556 | 1.520 |
Why?
|
| Heart Failure | 10 | 2024 | 2150 | 1.520 |
Why?
|
| Transplantation | 4 | 2023 | 31 | 1.480 |
Why?
|
| Travel | 4 | 2020 | 122 | 1.470 |
Why?
|
| Proportional Hazards Models | 33 | 2023 | 1201 | 1.440 |
Why?
|
| Nephrectomy | 11 | 2021 | 160 | 1.410 |
Why?
|
| Body Mass Index | 14 | 2024 | 2273 | 1.390 |
Why?
|
| Postoperative Complications | 19 | 2024 | 2483 | 1.380 |
Why?
|
| Patient Readmission | 6 | 2023 | 667 | 1.260 |
Why?
|
| Prognosis | 30 | 2024 | 3794 | 1.250 |
Why?
|
| Kidney Diseases | 11 | 2017 | 384 | 1.210 |
Why?
|
| Acute Kidney Injury | 12 | 2023 | 790 | 1.200 |
Why?
|
| Follow-Up Studies | 35 | 2024 | 4897 | 1.170 |
Why?
|
| Mycophenolic Acid | 9 | 2020 | 110 | 1.160 |
Why?
|
| Risk Assessment | 29 | 2022 | 3240 | 1.130 |
Why?
|
| Social Class | 2 | 2021 | 257 | 1.100 |
Why?
|
| Immunosuppressive Agents | 19 | 2020 | 853 | 1.080 |
Why?
|
| Cold Ischemia | 5 | 2024 | 30 | 1.060 |
Why?
|
| Organ Preservation | 5 | 2024 | 94 | 1.050 |
Why?
|
| Resource Allocation | 2 | 2018 | 39 | 1.040 |
Why?
|
| Mortality | 5 | 2019 | 307 | 1.010 |
Why?
|
| Hospitals, Low-Volume | 2 | 2017 | 22 | 1.010 |
Why?
|
| Hospitals, High-Volume | 2 | 2017 | 39 | 1.000 |
Why?
|
| Surgicenters | 2 | 2016 | 6 | 0.970 |
Why?
|
| Tissue and Organ Harvesting | 7 | 2024 | 72 | 0.920 |
Why?
|
| Adolescent | 50 | 2024 | 20393 | 0.920 |
Why?
|
| Tacrolimus | 7 | 2013 | 193 | 0.910 |
Why?
|
| Young Adult | 37 | 2021 | 12426 | 0.900 |
Why?
|
| Life Expectancy | 2 | 2018 | 61 | 0.880 |
Why?
|
| Solitary Kidney | 1 | 2023 | 5 | 0.880 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2024 | 71 | 0.870 |
Why?
|
| Kaplan-Meier Estimate | 17 | 2021 | 857 | 0.860 |
Why?
|
| Hospital Records | 2 | 2013 | 11 | 0.860 |
Why?
|
| Health Expenditures | 5 | 2020 | 179 | 0.840 |
Why?
|
| Survival Rate | 20 | 2024 | 1877 | 0.830 |
Why?
|
| Electronic Health Records | 12 | 2021 | 975 | 0.820 |
Why?
|
| Informed Consent | 1 | 2024 | 170 | 0.800 |
Why?
|
| Global Health | 2 | 2024 | 329 | 0.800 |
Why?
|
| Developing Countries | 1 | 2024 | 287 | 0.800 |
Why?
|
| Health Policy | 5 | 2016 | 353 | 0.780 |
Why?
|
| Benchmarking | 2 | 2021 | 176 | 0.740 |
Why?
|
| Nephrology | 3 | 2021 | 60 | 0.730 |
Why?
|
| Cardiovascular Diseases | 6 | 2022 | 2004 | 0.710 |
Why?
|
| Health Facilities | 3 | 2018 | 80 | 0.700 |
Why?
|
| Quality Improvement | 3 | 2019 | 1103 | 0.700 |
Why?
|
| Cadaver | 9 | 2019 | 306 | 0.690 |
Why?
|
| Nutrition Surveys | 4 | 2016 | 260 | 0.690 |
Why?
|
| Renal Insufficiency | 5 | 2018 | 149 | 0.670 |
Why?
|
| Pancreas Transplantation | 9 | 2014 | 75 | 0.670 |
Why?
|
| Hospital Mortality | 7 | 2020 | 850 | 0.670 |
Why?
|
| Aged, 80 and over | 34 | 2024 | 7086 | 0.670 |
Why?
|
| Liver Failure, Acute | 1 | 2020 | 64 | 0.670 |
Why?
|
| Cohort Studies | 25 | 2024 | 5420 | 0.650 |
Why?
|
| Kidney Calculi | 4 | 2021 | 35 | 0.650 |
Why?
|
| Cytomegalovirus Infections | 5 | 2024 | 189 | 0.630 |
Why?
|
| Ohio | 13 | 2018 | 152 | 0.630 |
Why?
|
| Reoperation | 5 | 2015 | 545 | 0.630 |
Why?
|
| Myasthenia Gravis | 3 | 2024 | 21 | 0.610 |
Why?
|
| Hospitalization | 11 | 2023 | 2070 | 0.610 |
Why?
|
| Isoantibodies | 5 | 2024 | 51 | 0.600 |
Why?
|
| Quality Assurance, Health Care | 4 | 2019 | 318 | 0.590 |
Why?
|
| Emergency Service, Hospital | 11 | 2022 | 1902 | 0.590 |
Why?
|
| Receptors, Interleukin-2 | 2 | 2015 | 66 | 0.590 |
Why?
|
| Continuity of Patient Care | 2 | 2024 | 275 | 0.580 |
Why?
|
| Cause of Death | 10 | 2021 | 393 | 0.580 |
Why?
|
| Residence Characteristics | 2 | 2022 | 328 | 0.570 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2017 | 248 | 0.560 |
Why?
|
| BK Virus | 4 | 2014 | 13 | 0.560 |
Why?
|
| Decision Making | 3 | 2019 | 851 | 0.550 |
Why?
|
| Polyomavirus Infections | 4 | 2014 | 28 | 0.550 |
Why?
|
| Tumor Virus Infections | 4 | 2014 | 46 | 0.550 |
Why?
|
| Population Health | 1 | 2018 | 46 | 0.540 |
Why?
|
| Perfusion | 4 | 2024 | 197 | 0.540 |
Why?
|
| Surgical Procedures, Operative | 1 | 2019 | 244 | 0.540 |
Why?
|
| Hospitals | 4 | 2020 | 637 | 0.540 |
Why?
|
| Incidence | 16 | 2024 | 2644 | 0.530 |
Why?
|
| Weight Loss | 4 | 2013 | 734 | 0.520 |
Why?
|
| Patient Discharge | 3 | 2022 | 857 | 0.520 |
Why?
|
| HLA Antigens | 4 | 2011 | 234 | 0.520 |
Why?
|
| Obesity | 6 | 2024 | 2883 | 0.520 |
Why?
|
| Cardiomyopathy, Restrictive | 1 | 2016 | 9 | 0.520 |
Why?
|
| Delivery of Health Care | 3 | 2015 | 894 | 0.510 |
Why?
|
| Medical Staff, Hospital | 2 | 2013 | 78 | 0.510 |
Why?
|
| Allografts | 7 | 2021 | 136 | 0.510 |
Why?
|
| Bayes Theorem | 2 | 2017 | 375 | 0.510 |
Why?
|
| Logistic Models | 14 | 2017 | 1988 | 0.500 |
Why?
|
| Prospective Studies | 24 | 2023 | 7133 | 0.500 |
Why?
|
| Guideline Adherence | 3 | 2019 | 526 | 0.500 |
Why?
|
| Clinical Trials as Topic | 8 | 2023 | 1004 | 0.500 |
Why?
|
| Referral and Consultation | 3 | 2021 | 732 | 0.490 |
Why?
|
| Survivors | 2 | 2018 | 464 | 0.480 |
Why?
|
| Models, Biological | 3 | 2017 | 1722 | 0.480 |
Why?
|
| Metabolic Syndrome | 6 | 2018 | 339 | 0.480 |
Why?
|
| Heart Valve Diseases | 2 | 2016 | 152 | 0.470 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2016 | 132 | 0.470 |
Why?
|
| Hospital Costs | 1 | 2015 | 114 | 0.470 |
Why?
|
| Documentation | 2 | 2013 | 184 | 0.460 |
Why?
|
| Histocompatibility Testing | 3 | 2024 | 120 | 0.460 |
Why?
|
| Medicaid | 3 | 2024 | 433 | 0.460 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2017 | 643 | 0.460 |
Why?
|
| Practice Patterns, Physicians' | 5 | 2019 | 1266 | 0.450 |
Why?
|
| Models, Theoretical | 2 | 2023 | 547 | 0.450 |
Why?
|
| Comorbidity | 14 | 2023 | 1547 | 0.440 |
Why?
|
| Age Factors | 13 | 2021 | 3144 | 0.440 |
Why?
|
| Death | 3 | 2024 | 121 | 0.430 |
Why?
|
| Testosterone | 2 | 2014 | 372 | 0.430 |
Why?
|
| Odds Ratio | 9 | 2019 | 1023 | 0.420 |
Why?
|
| Dog Diseases | 2 | 2010 | 52 | 0.420 |
Why?
|
| Methylprednisolone | 1 | 2013 | 83 | 0.410 |
Why?
|
| Severity of Illness Index | 12 | 2024 | 2742 | 0.410 |
Why?
|
| Nephrologists | 2 | 2023 | 12 | 0.410 |
Why?
|
| Health Care Rationing | 2 | 2010 | 57 | 0.400 |
Why?
|
| Blood Specimen Collection | 3 | 2017 | 35 | 0.400 |
Why?
|
| Multivariate Analysis | 14 | 2017 | 1502 | 0.400 |
Why?
|
| Quality of Health Care | 6 | 2023 | 608 | 0.400 |
Why?
|
| Antilymphocyte Serum | 5 | 2020 | 63 | 0.400 |
Why?
|
| Insurance, Health | 5 | 2018 | 267 | 0.400 |
Why?
|
| Hemolysis | 4 | 2017 | 199 | 0.400 |
Why?
|
| Antigens, CD19 | 1 | 2013 | 115 | 0.400 |
Why?
|
| Socioeconomic Factors | 4 | 2024 | 1214 | 0.390 |
Why?
|
| Inpatients | 2 | 2015 | 467 | 0.390 |
Why?
|
| Patient Participation | 3 | 2015 | 414 | 0.390 |
Why?
|
| Uric Acid | 5 | 2018 | 161 | 0.390 |
Why?
|
| Intensive Care Units | 3 | 2013 | 738 | 0.390 |
Why?
|
| Pulmonary Embolism | 1 | 2014 | 211 | 0.380 |
Why?
|
| Brain Ischemia | 3 | 2020 | 321 | 0.370 |
Why?
|
| Community Health Services | 1 | 2013 | 227 | 0.370 |
Why?
|
| Health Status Indicators | 1 | 2012 | 167 | 0.360 |
Why?
|
| Azathioprine | 2 | 2020 | 50 | 0.360 |
Why?
|
| Internship and Residency | 3 | 2021 | 1053 | 0.360 |
Why?
|
| Histocompatibility | 2 | 2017 | 26 | 0.360 |
Why?
|
| Sex Factors | 7 | 2024 | 1968 | 0.350 |
Why?
|
| Cat Diseases | 1 | 2010 | 19 | 0.350 |
Why?
|
| Antibodies, Monoclonal | 3 | 2017 | 1367 | 0.350 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2019 | 1368 | 0.350 |
Why?
|
| Creatinine | 9 | 2023 | 491 | 0.350 |
Why?
|
| Policy | 2 | 2023 | 144 | 0.350 |
Why?
|
| Blood Pressure Determination | 4 | 2019 | 148 | 0.350 |
Why?
|
| Government Regulation | 1 | 2010 | 49 | 0.340 |
Why?
|
| Predictive Value of Tests | 9 | 2022 | 1952 | 0.340 |
Why?
|
| Adipose Tissue | 1 | 2014 | 592 | 0.340 |
Why?
|
| Laparotomy | 1 | 2010 | 106 | 0.340 |
Why?
|
| Stroke | 4 | 2020 | 1071 | 0.330 |
Why?
|
| Models, Statistical | 6 | 2022 | 623 | 0.330 |
Why?
|
| Frailty | 2 | 2023 | 153 | 0.330 |
Why?
|
| Cross-Sectional Studies | 8 | 2024 | 5066 | 0.330 |
Why?
|
| Intraoperative Complications | 1 | 2010 | 131 | 0.320 |
Why?
|
| Motor Activity | 1 | 2014 | 676 | 0.320 |
Why?
|
| Enzyme Inhibitors | 2 | 2014 | 827 | 0.320 |
Why?
|
| Antibodies | 3 | 2022 | 398 | 0.320 |
Why?
|
| Apolipoprotein L1 | 2 | 2021 | 13 | 0.320 |
Why?
|
| Transplantation Tolerance | 1 | 2009 | 35 | 0.320 |
Why?
|
| Syphilis | 2 | 2022 | 32 | 0.320 |
Why?
|
| Lithotripsy | 2 | 2019 | 43 | 0.320 |
Why?
|
| Heart Defects, Congenital | 1 | 2016 | 758 | 0.310 |
Why?
|
| Machine Learning | 2 | 2025 | 443 | 0.310 |
Why?
|
| Calcineurin Inhibitors | 2 | 2008 | 68 | 0.310 |
Why?
|
| Ureter | 2 | 2019 | 35 | 0.310 |
Why?
|
| Steroids | 1 | 2009 | 158 | 0.310 |
Why?
|
| Research | 2 | 2010 | 416 | 0.300 |
Why?
|
| Risk | 5 | 2019 | 854 | 0.300 |
Why?
|
| Sirolimus | 6 | 2014 | 266 | 0.290 |
Why?
|
| Databases, Factual | 10 | 2024 | 1269 | 0.290 |
Why?
|
| Kidney Function Tests | 5 | 2024 | 152 | 0.290 |
Why?
|
| Body Weight | 2 | 2009 | 940 | 0.290 |
Why?
|
| Lung | 2 | 2022 | 3930 | 0.290 |
Why?
|
| B-Lymphocytes | 1 | 2013 | 815 | 0.280 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 5 | 2017 | 573 | 0.280 |
Why?
|
| Overweight | 1 | 2012 | 531 | 0.280 |
Why?
|
| Disease Progression | 10 | 2021 | 2635 | 0.270 |
Why?
|
| Veterans | 1 | 2018 | 1398 | 0.270 |
Why?
|
| Child | 14 | 2024 | 20883 | 0.260 |
Why?
|
| Hypertension | 6 | 2017 | 1242 | 0.260 |
Why?
|
| Laparoscopy | 1 | 2010 | 451 | 0.260 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2020 | 2441 | 0.250 |
Why?
|
| Cardiopulmonary Resuscitation | 2 | 2021 | 232 | 0.250 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2017 | 759 | 0.250 |
Why?
|
| Cardiac Surgical Procedures | 3 | 2022 | 499 | 0.250 |
Why?
|
| Transplantation, Homologous | 6 | 2018 | 401 | 0.250 |
Why?
|
| Certification | 2 | 2017 | 94 | 0.250 |
Why?
|
| Emigrants and Immigrants | 1 | 2007 | 122 | 0.240 |
Why?
|
| Brain Death | 3 | 2024 | 46 | 0.240 |
Why?
|
| Liver Diseases | 2 | 2024 | 290 | 0.240 |
Why?
|
| Perioperative Period | 2 | 2016 | 49 | 0.230 |
Why?
|
| Sex Distribution | 2 | 2017 | 359 | 0.230 |
Why?
|
| Patient Navigation | 2 | 2017 | 79 | 0.230 |
Why?
|
| Viremia | 3 | 2014 | 131 | 0.230 |
Why?
|
| Quality of Life | 5 | 2022 | 2704 | 0.230 |
Why?
|
| Chi-Square Distribution | 7 | 2016 | 516 | 0.230 |
Why?
|
| Fructose | 2 | 2018 | 106 | 0.230 |
Why?
|
| Kidney Neoplasms | 1 | 2008 | 350 | 0.230 |
Why?
|
| Reproducibility of Results | 4 | 2024 | 3083 | 0.220 |
Why?
|
| Research Design | 2 | 2017 | 1044 | 0.220 |
Why?
|
| Calibration | 1 | 2024 | 140 | 0.220 |
Why?
|
| Insurance Coverage | 3 | 2016 | 219 | 0.210 |
Why?
|
| Costs and Cost Analysis | 4 | 2024 | 201 | 0.210 |
Why?
|
| Blood Pressure | 4 | 2019 | 1736 | 0.210 |
Why?
|
| Clinical Decision-Making | 2 | 2017 | 303 | 0.210 |
Why?
|
| Ureteroscopy | 2 | 2019 | 16 | 0.210 |
Why?
|
| Waist Circumference | 2 | 2014 | 138 | 0.210 |
Why?
|
| Child, Preschool | 7 | 2024 | 10517 | 0.200 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2023 | 102 | 0.200 |
Why?
|
| Ambulatory Care Facilities | 3 | 2017 | 228 | 0.200 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2017 | 1279 | 0.200 |
Why?
|
| Transplantation Conditioning | 3 | 2009 | 166 | 0.200 |
Why?
|
| Chronic Disease | 9 | 2024 | 1720 | 0.200 |
Why?
|
| Chlamydia | 1 | 2022 | 9 | 0.200 |
Why?
|
| Pandemics | 2 | 2021 | 1488 | 0.200 |
Why?
|
| Hospital Charges | 2 | 2019 | 41 | 0.190 |
Why?
|
| Diabetic Nephropathies | 3 | 2017 | 284 | 0.190 |
Why?
|
| Patient Education as Topic | 3 | 2017 | 743 | 0.190 |
Why?
|
| Data Collection | 1 | 2025 | 650 | 0.190 |
Why?
|
| Artificial Intelligence | 1 | 2025 | 246 | 0.190 |
Why?
|
| Cytomegalovirus | 4 | 2024 | 154 | 0.190 |
Why?
|
| Defibrillators, Implantable | 2 | 2015 | 300 | 0.190 |
Why?
|
| Family | 2 | 2024 | 657 | 0.190 |
Why?
|
| Urologic Diseases | 2 | 2019 | 38 | 0.190 |
Why?
|
| Stomach Diseases | 1 | 2021 | 20 | 0.180 |
Why?
|
| Glomerulonephritis, IGA | 1 | 2021 | 10 | 0.180 |
Why?
|
| Alemtuzumab | 3 | 2017 | 15 | 0.180 |
Why?
|
| Gonorrhea | 1 | 2022 | 57 | 0.180 |
Why?
|
| Chlamydia Infections | 1 | 2022 | 73 | 0.180 |
Why?
|
| Histamine H2 Antagonists | 1 | 2021 | 29 | 0.180 |
Why?
|
| Motivation | 2 | 2016 | 546 | 0.180 |
Why?
|
| Genital Neoplasms, Female | 1 | 2022 | 82 | 0.180 |
Why?
|
| Practice Guidelines as Topic | 3 | 2019 | 1501 | 0.180 |
Why?
|
| Proteinuria | 1 | 2021 | 91 | 0.170 |
Why?
|
| Data Interpretation, Statistical | 3 | 2019 | 335 | 0.170 |
Why?
|
| Proton Pump Inhibitors | 1 | 2021 | 100 | 0.170 |
Why?
|
| Podocytes | 1 | 2021 | 52 | 0.170 |
Why?
|
| Job Satisfaction | 1 | 2022 | 203 | 0.170 |
Why?
|
| Abdominal Fat | 1 | 2020 | 40 | 0.170 |
Why?
|
| Liver | 3 | 2023 | 1839 | 0.170 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2022 | 150 | 0.170 |
Why?
|
| Nephrolithotomy, Percutaneous | 1 | 2019 | 3 | 0.170 |
Why?
|
| Acute Disease | 5 | 2017 | 980 | 0.170 |
Why?
|
| Insurance Benefits | 1 | 2019 | 12 | 0.170 |
Why?
|
| Ventricular Function, Left | 3 | 2019 | 527 | 0.170 |
Why?
|
| Androgen Antagonists | 1 | 2020 | 79 | 0.170 |
Why?
|
| Serine Endopeptidases | 1 | 2020 | 118 | 0.160 |
Why?
|
| Survival Analysis | 5 | 2010 | 1274 | 0.160 |
Why?
|
| Income | 3 | 2023 | 189 | 0.160 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2023 | 282 | 0.160 |
Why?
|
| Health Facility Administration | 2 | 2010 | 6 | 0.160 |
Why?
|
| Magnesium | 1 | 2020 | 153 | 0.160 |
Why?
|
| Viral Load | 3 | 2016 | 448 | 0.160 |
Why?
|
| Ureteral Calculi | 1 | 2019 | 13 | 0.160 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 171 | 0.160 |
Why?
|
| Triticum | 1 | 2019 | 11 | 0.160 |
Why?
|
| Thrombectomy | 1 | 2019 | 59 | 0.160 |
Why?
|
| Myocardial Revascularization | 2 | 2016 | 72 | 0.160 |
Why?
|
| Career Choice | 1 | 2021 | 207 | 0.160 |
Why?
|
| Decision Trees | 1 | 2019 | 90 | 0.160 |
Why?
|
| Biomarkers | 7 | 2020 | 3973 | 0.160 |
Why?
|
| Patient Admission | 1 | 2020 | 182 | 0.150 |
Why?
|
| Risk Adjustment | 2 | 2010 | 79 | 0.150 |
Why?
|
| Thrombolytic Therapy | 1 | 2019 | 137 | 0.150 |
Why?
|
| Internal Medicine | 1 | 2021 | 247 | 0.150 |
Why?
|
| Medical Futility | 1 | 2018 | 24 | 0.150 |
Why?
|
| Health Care Costs | 2 | 2020 | 367 | 0.150 |
Why?
|
| Propensity Score | 5 | 2020 | 265 | 0.150 |
Why?
|
| Adiposity | 2 | 2014 | 504 | 0.150 |
Why?
|
| Biopsy | 4 | 2021 | 1097 | 0.150 |
Why?
|
| Immunologic Factors | 1 | 2020 | 231 | 0.150 |
Why?
|
| Stroke Volume | 2 | 2019 | 592 | 0.150 |
Why?
|
| Patient Transfer | 1 | 2020 | 162 | 0.150 |
Why?
|
| Terminology as Topic | 1 | 2019 | 204 | 0.150 |
Why?
|
| Killer Cells, Natural | 2 | 2014 | 427 | 0.150 |
Why?
|
| Heat-Shock Response | 1 | 2018 | 72 | 0.150 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2016 | 985 | 0.150 |
Why?
|
| Hypotension | 1 | 2019 | 116 | 0.140 |
Why?
|
| Gout Suppressants | 1 | 2017 | 17 | 0.140 |
Why?
|
| Phlebotomy | 1 | 2017 | 18 | 0.140 |
Why?
|
| Hyperuricemia | 1 | 2017 | 44 | 0.140 |
Why?
|
| Employment | 2 | 2016 | 167 | 0.140 |
Why?
|
| Hypernatremia | 1 | 2017 | 9 | 0.140 |
Why?
|
| Diabetes Complications | 3 | 2009 | 224 | 0.140 |
Why?
|
| Heart Valve Prosthesis | 1 | 2019 | 112 | 0.140 |
Why?
|
| Infant | 6 | 2023 | 9024 | 0.140 |
Why?
|
| Health Records, Personal | 1 | 2017 | 26 | 0.140 |
Why?
|
| Vitamin D | 2 | 2011 | 384 | 0.140 |
Why?
|
| Aftercare | 1 | 2019 | 205 | 0.140 |
Why?
|
| Fatigue | 1 | 2019 | 318 | 0.140 |
Why?
|
| Cholesterol, HDL | 1 | 2018 | 205 | 0.140 |
Why?
|
| Drug Overdose | 1 | 2021 | 322 | 0.140 |
Why?
|
| Dendritic Cells | 3 | 2005 | 478 | 0.140 |
Why?
|
| Hyponatremia | 1 | 2017 | 40 | 0.140 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2019 | 121 | 0.140 |
Why?
|
| Body Image | 1 | 2018 | 84 | 0.130 |
Why?
|
| Treponema pallidum | 1 | 2016 | 8 | 0.130 |
Why?
|
| Case-Control Studies | 6 | 2022 | 3381 | 0.130 |
Why?
|
| Financing, Personal | 1 | 2016 | 26 | 0.130 |
Why?
|
| Laboratories, Hospital | 1 | 2016 | 14 | 0.130 |
Why?
|
| Multiple Sclerosis | 1 | 2022 | 436 | 0.130 |
Why?
|
| Analgesics, Opioid | 3 | 2021 | 913 | 0.130 |
Why?
|
| Graft vs Host Disease | 4 | 2008 | 241 | 0.130 |
Why?
|
| Patient Preference | 1 | 2018 | 185 | 0.130 |
Why?
|
| Parental Leave | 1 | 2016 | 24 | 0.130 |
Why?
|
| Aortic Valve Stenosis | 1 | 2019 | 218 | 0.130 |
Why?
|
| Surveys and Questionnaires | 7 | 2022 | 5406 | 0.130 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2016 | 52 | 0.130 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2020 | 320 | 0.130 |
Why?
|
| Personal Satisfaction | 1 | 2018 | 200 | 0.120 |
Why?
|
| Contrast Media | 1 | 2018 | 394 | 0.120 |
Why?
|
| HIV Seropositivity | 1 | 2016 | 119 | 0.120 |
Why?
|
| Hospitals, General | 1 | 2015 | 21 | 0.120 |
Why?
|
| Hypokalemia | 1 | 2015 | 24 | 0.120 |
Why?
|
| Specimen Handling | 1 | 2016 | 164 | 0.120 |
Why?
|
| Hyperkalemia | 1 | 2015 | 24 | 0.120 |
Why?
|
| Affect | 1 | 2018 | 286 | 0.120 |
Why?
|
| Stents | 1 | 2019 | 504 | 0.120 |
Why?
|
| Health Plan Implementation | 1 | 2016 | 137 | 0.120 |
Why?
|
| Induction Chemotherapy | 1 | 2015 | 70 | 0.120 |
Why?
|
| Regression Analysis | 3 | 2014 | 993 | 0.120 |
Why?
|
| HIV Infections | 2 | 2022 | 2720 | 0.120 |
Why?
|
| Catheters | 1 | 2015 | 68 | 0.120 |
Why?
|
| Electric Countershock | 1 | 2015 | 105 | 0.120 |
Why?
|
| Drug Therapy, Combination | 4 | 2020 | 1040 | 0.120 |
Why?
|
| Palliative Care | 1 | 2021 | 725 | 0.110 |
Why?
|
| Longitudinal Studies | 3 | 2024 | 2717 | 0.110 |
Why?
|
| Length of Stay | 3 | 2016 | 1127 | 0.110 |
Why?
|
| Reimbursement Mechanisms | 1 | 2015 | 84 | 0.110 |
Why?
|
| Equipment Design | 1 | 2016 | 514 | 0.110 |
Why?
|
| Myocardial Ischemia | 1 | 2016 | 258 | 0.110 |
Why?
|
| Algorithms | 3 | 2022 | 1622 | 0.110 |
Why?
|
| Coronary Artery Bypass | 1 | 2016 | 224 | 0.110 |
Why?
|
| Drug Prescriptions | 1 | 2016 | 248 | 0.110 |
Why?
|
| Fear | 1 | 2018 | 350 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 3 | 2016 | 569 | 0.110 |
Why?
|
| Chelating Agents | 1 | 2014 | 68 | 0.110 |
Why?
|
| Intention | 2 | 2015 | 162 | 0.110 |
Why?
|
| Hemodialysis, Home | 1 | 2014 | 8 | 0.110 |
Why?
|
| Respiratory Function Tests | 1 | 2016 | 586 | 0.110 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2018 | 635 | 0.110 |
Why?
|
| Information Services | 1 | 2014 | 47 | 0.110 |
Why?
|
| Opioid-Related Disorders | 1 | 2021 | 484 | 0.110 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 759 | 0.110 |
Why?
|
| Health Status | 3 | 2021 | 755 | 0.110 |
Why?
|
| Prevalence | 5 | 2024 | 2564 | 0.110 |
Why?
|
| Atrial Fibrillation | 1 | 2018 | 376 | 0.110 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2015 | 179 | 0.110 |
Why?
|
| Vascular Resistance | 1 | 2015 | 371 | 0.110 |
Why?
|
| HLA-C Antigens | 1 | 2014 | 35 | 0.110 |
Why?
|
| Prosthesis-Related Infections | 1 | 2014 | 75 | 0.110 |
Why?
|
| Selection Bias | 2 | 2010 | 37 | 0.110 |
Why?
|
| Primary Prevention | 1 | 2015 | 188 | 0.110 |
Why?
|
| Postpartum Period | 1 | 2016 | 332 | 0.110 |
Why?
|
| Choice Behavior | 1 | 2015 | 165 | 0.110 |
Why?
|
| House Calls | 1 | 2014 | 123 | 0.100 |
Why?
|
| Florida | 2 | 2011 | 93 | 0.100 |
Why?
|
| Phosphates | 1 | 2014 | 180 | 0.100 |
Why?
|
| Patients | 1 | 2015 | 167 | 0.100 |
Why?
|
| Pancreatic Diseases | 1 | 2013 | 70 | 0.100 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2013 | 64 | 0.100 |
Why?
|
| Receptors, KIR | 1 | 2014 | 96 | 0.100 |
Why?
|
| Urologic Surgical Procedures | 1 | 2014 | 107 | 0.100 |
Why?
|
| Lung Diseases | 1 | 2019 | 742 | 0.100 |
Why?
|
| Public Health | 1 | 2017 | 484 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 2 | 2013 | 1038 | 0.100 |
Why?
|
| Prostatic Neoplasms | 1 | 2020 | 1016 | 0.100 |
Why?
|
| Program Development | 1 | 2015 | 357 | 0.100 |
Why?
|
| Hyperparathyroidism | 1 | 2012 | 11 | 0.100 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2015 | 317 | 0.100 |
Why?
|
| Alkaline Phosphatase | 1 | 2013 | 146 | 0.100 |
Why?
|
| HLA-DQ Antigens | 2 | 2024 | 179 | 0.100 |
Why?
|
| Dogs | 2 | 2010 | 381 | 0.100 |
Why?
|
| Hypoalbuminemia | 1 | 2012 | 30 | 0.100 |
Why?
|
| Breast Feeding | 1 | 2016 | 424 | 0.100 |
Why?
|
| Triglycerides | 2 | 2012 | 527 | 0.100 |
Why?
|
| Peritoneal Dialysis | 1 | 2014 | 95 | 0.100 |
Why?
|
| Cardiomyopathies | 1 | 2016 | 340 | 0.100 |
Why?
|
| Whole-Body Irradiation | 2 | 2009 | 76 | 0.100 |
Why?
|
| Insulin Resistance | 1 | 2020 | 1165 | 0.100 |
Why?
|
| Patient Care Team | 1 | 2017 | 605 | 0.100 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2015 | 385 | 0.100 |
Why?
|
| Anthropometry | 1 | 2012 | 204 | 0.090 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2012 | 94 | 0.090 |
Why?
|
| Attitude of Health Personnel | 3 | 2021 | 1098 | 0.090 |
Why?
|
| Genetic Variation | 1 | 2017 | 937 | 0.090 |
Why?
|
| Quality Control | 2 | 2016 | 163 | 0.090 |
Why?
|
| Bicarbonates | 1 | 2011 | 42 | 0.090 |
Why?
|
| Skin | 1 | 2016 | 725 | 0.090 |
Why?
|
| Transplantation Immunology | 1 | 2011 | 34 | 0.090 |
Why?
|
| Herpesviridae Infections | 1 | 2012 | 141 | 0.090 |
Why?
|
| Diabetes Mellitus | 3 | 2016 | 1001 | 0.090 |
Why?
|
| Hypophosphatemia | 1 | 2011 | 17 | 0.090 |
Why?
|
| International Classification of Diseases | 2 | 2022 | 122 | 0.090 |
Why?
|
| Hospitals, University | 1 | 2011 | 179 | 0.090 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2016 | 467 | 0.090 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2010 | 14 | 0.090 |
Why?
|
| Inflammation | 2 | 2020 | 2736 | 0.090 |
Why?
|
| Renin | 1 | 2010 | 32 | 0.090 |
Why?
|
| Caloric Restriction | 1 | 2012 | 111 | 0.090 |
Why?
|
| Urban Population | 1 | 2013 | 441 | 0.090 |
Why?
|
| Glomerulonephritis | 1 | 2010 | 46 | 0.090 |
Why?
|
| Physical Phenomena | 1 | 2010 | 13 | 0.090 |
Why?
|
| Cats | 1 | 2010 | 208 | 0.090 |
Why?
|
| Virus Activation | 2 | 2013 | 88 | 0.080 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 1 | 2014 | 254 | 0.080 |
Why?
|
| Cyclosporine | 3 | 2011 | 263 | 0.080 |
Why?
|
| Mothers | 1 | 2016 | 729 | 0.080 |
Why?
|
| Antimetabolites | 1 | 2009 | 23 | 0.080 |
Why?
|
| Polycythemia | 1 | 2010 | 22 | 0.080 |
Why?
|
| Allopurinol | 1 | 2009 | 62 | 0.080 |
Why?
|
| Hemodialysis Units, Hospital | 1 | 2009 | 5 | 0.080 |
Why?
|
| National Health Programs | 1 | 2009 | 17 | 0.080 |
Why?
|
| Heart Block | 1 | 2009 | 40 | 0.080 |
Why?
|
| Myeloablative Agonists | 1 | 2009 | 21 | 0.080 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2009 | 28 | 0.080 |
Why?
|
| Busulfan | 1 | 2009 | 15 | 0.080 |
Why?
|
| Organizational Innovation | 1 | 2010 | 139 | 0.080 |
Why?
|
| Vidarabine | 1 | 2009 | 30 | 0.080 |
Why?
|
| Rural Population | 1 | 2013 | 518 | 0.080 |
Why?
|
| Least-Squares Analysis | 1 | 2009 | 78 | 0.080 |
Why?
|
| Vitamin D Deficiency | 1 | 2011 | 176 | 0.080 |
Why?
|
| ABO Blood-Group System | 1 | 2009 | 39 | 0.080 |
Why?
|
| Topography, Medical | 1 | 2009 | 11 | 0.080 |
Why?
|
| Health Behavior | 1 | 2015 | 741 | 0.080 |
Why?
|
| Salaries and Fringe Benefits | 2 | 2022 | 55 | 0.080 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2009 | 91 | 0.080 |
Why?
|
| Herpesvirus 3, Human | 1 | 2012 | 331 | 0.080 |
Why?
|
| Energy Intake | 1 | 2012 | 461 | 0.080 |
Why?
|
| United Kingdom | 1 | 2009 | 257 | 0.080 |
Why?
|
| Pacemaker, Artificial | 1 | 2009 | 110 | 0.080 |
Why?
|
| Patient Satisfaction | 2 | 2014 | 634 | 0.070 |
Why?
|
| Models, Economic | 1 | 2008 | 53 | 0.070 |
Why?
|
| Recurrence | 4 | 2021 | 1007 | 0.070 |
Why?
|
| Minority Groups | 1 | 2010 | 249 | 0.070 |
Why?
|
| Control Groups | 1 | 2007 | 11 | 0.070 |
Why?
|
| Respiratory Insufficiency | 1 | 2011 | 313 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2014 | 3628 | 0.070 |
Why?
|
| Blood Transfusion | 1 | 2009 | 296 | 0.070 |
Why?
|
| Health Care Surveys | 2 | 2021 | 559 | 0.070 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 1206 | 0.060 |
Why?
|
| Patient Care | 1 | 2007 | 109 | 0.060 |
Why?
|
| Hypercalcemia | 1 | 2006 | 21 | 0.060 |
Why?
|
| Infant, Newborn | 2 | 2009 | 5762 | 0.060 |
Why?
|
| Accreditation | 1 | 2006 | 80 | 0.060 |
Why?
|
| Naphthalenes | 1 | 2006 | 57 | 0.060 |
Why?
|
| Transportation | 2 | 2016 | 50 | 0.060 |
Why?
|
| Age Distribution | 1 | 2006 | 372 | 0.060 |
Why?
|
| Pulsatile Flow | 1 | 2005 | 59 | 0.060 |
Why?
|
| Interleukin-12 | 1 | 2005 | 118 | 0.060 |
Why?
|
| Biomedical Research | 1 | 2011 | 638 | 0.060 |
Why?
|
| Critical Illness | 1 | 2011 | 758 | 0.060 |
Why?
|
| T-Lymphocytes | 1 | 2013 | 1928 | 0.060 |
Why?
|
| Leukocytes | 1 | 2006 | 304 | 0.060 |
Why?
|
| Cryopreservation | 1 | 2005 | 97 | 0.060 |
Why?
|
| Antigens | 1 | 2006 | 355 | 0.060 |
Why?
|
| Stem Cell Transplantation | 1 | 2005 | 166 | 0.060 |
Why?
|
| Withholding Treatment | 1 | 2004 | 71 | 0.060 |
Why?
|
| Seroepidemiologic Studies | 1 | 2024 | 156 | 0.060 |
Why?
|
| Bacterial Infections | 1 | 2006 | 237 | 0.060 |
Why?
|
| Foundations | 1 | 2024 | 24 | 0.060 |
Why?
|
| Consensus | 2 | 2018 | 616 | 0.050 |
Why?
|
| Immunity, Cellular | 1 | 2005 | 265 | 0.050 |
Why?
|
| Transplantation, Heterologous | 1 | 2024 | 192 | 0.050 |
Why?
|
| Heterografts | 1 | 2024 | 131 | 0.050 |
Why?
|
| Eligibility Determination | 1 | 2024 | 63 | 0.050 |
Why?
|
| Immunocompromised Host | 2 | 2020 | 198 | 0.050 |
Why?
|
| Leukemia | 1 | 2005 | 230 | 0.050 |
Why?
|
| Lithium | 1 | 2023 | 37 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2020 | 1288 | 0.050 |
Why?
|
| Arterial Pressure | 2 | 2014 | 117 | 0.050 |
Why?
|
| Diet | 1 | 2010 | 1213 | 0.050 |
Why?
|
| Shock | 1 | 2024 | 92 | 0.050 |
Why?
|
| Urinalysis | 1 | 2023 | 75 | 0.050 |
Why?
|
| Health Equity | 1 | 2024 | 83 | 0.050 |
Why?
|
| Hypertension, Pulmonary | 1 | 2014 | 1894 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 2061 | 0.050 |
Why?
|
| Phosphorus | 2 | 2014 | 93 | 0.050 |
Why?
|
| Laboratories | 1 | 2023 | 110 | 0.050 |
Why?
|
| Liver Cirrhosis | 1 | 2024 | 280 | 0.050 |
Why?
|
| Health Personnel | 1 | 2008 | 652 | 0.050 |
Why?
|
| Sodium | 1 | 2022 | 206 | 0.050 |
Why?
|
| Relative Value Scales | 1 | 2021 | 5 | 0.050 |
Why?
|
| Microscopy | 1 | 2023 | 141 | 0.050 |
Why?
|
| Educational Status | 1 | 2024 | 470 | 0.050 |
Why?
|
| Area Under Curve | 1 | 2022 | 304 | 0.050 |
Why?
|
| Recovery of Function | 2 | 2019 | 642 | 0.050 |
Why?
|
| Brazil | 1 | 2021 | 154 | 0.050 |
Why?
|
| Likelihood Functions | 1 | 2021 | 138 | 0.050 |
Why?
|
| Unrelated Donors | 1 | 2021 | 36 | 0.050 |
Why?
|
| Work-Life Balance | 1 | 2021 | 19 | 0.040 |
Why?
|
| Alleles | 1 | 2024 | 845 | 0.040 |
Why?
|
| HIV | 1 | 2022 | 226 | 0.040 |
Why?
|
| Workload | 1 | 2022 | 153 | 0.040 |
Why?
|
| Europe | 1 | 2021 | 364 | 0.040 |
Why?
|
| Databases as Topic | 3 | 2005 | 59 | 0.040 |
Why?
|
| Exercise | 1 | 2012 | 1925 | 0.040 |
Why?
|
| Disease-Free Survival | 3 | 2008 | 648 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2005 | 1198 | 0.040 |
Why?
|
| ROC Curve | 1 | 2022 | 503 | 0.040 |
Why?
|
| Animals | 4 | 2024 | 35361 | 0.040 |
Why?
|
| United States Public Health Service | 1 | 2019 | 9 | 0.040 |
Why?
|
| International Cooperation | 1 | 2020 | 174 | 0.040 |
Why?
|
| Clinical Clerkship | 1 | 2021 | 95 | 0.040 |
Why?
|
| Prednisone | 1 | 2020 | 233 | 0.040 |
Why?
|
| Probability | 1 | 2020 | 306 | 0.040 |
Why?
|
| Endothelial Cells | 1 | 2005 | 749 | 0.040 |
Why?
|
| Mentors | 1 | 2021 | 178 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2023 | 943 | 0.040 |
Why?
|
| Calcium Oxalate | 1 | 2018 | 5 | 0.040 |
Why?
|
| Injections, Intra-Arterial | 1 | 2018 | 25 | 0.040 |
Why?
|
| Renal Replacement Therapy | 1 | 2019 | 87 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2019 | 110 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2019 | 329 | 0.040 |
Why?
|
| Injections, Intravenous | 1 | 2018 | 201 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2020 | 636 | 0.040 |
Why?
|
| Linear Models | 1 | 2020 | 819 | 0.040 |
Why?
|
| Terminal Care | 1 | 2021 | 237 | 0.040 |
Why?
|
| Pain, Postoperative | 1 | 2020 | 233 | 0.040 |
Why?
|
| Autografts | 1 | 2017 | 42 | 0.040 |
Why?
|
| Joint Commission on Accreditation of Healthcare Organizations | 1 | 2017 | 8 | 0.040 |
Why?
|
| Lipids | 2 | 2013 | 625 | 0.040 |
Why?
|
| Hematologic Neoplasms | 2 | 2009 | 140 | 0.030 |
Why?
|
| Fee-for-Service Plans | 1 | 2017 | 88 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2014 | 1587 | 0.030 |
Why?
|
| Silver Staining | 1 | 2016 | 17 | 0.030 |
Why?
|
| Reference Values | 2 | 2011 | 793 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2018 | 2535 | 0.030 |
Why?
|
| Coronary Angiography | 1 | 2018 | 306 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2020 | 751 | 0.030 |
Why?
|
| Calcium | 2 | 2014 | 1213 | 0.030 |
Why?
|
| Minnesota | 1 | 2016 | 149 | 0.030 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2016 | 266 | 0.030 |
Why?
|
| Echocardiography | 1 | 2019 | 629 | 0.030 |
Why?
|
| Genotype | 1 | 2021 | 1839 | 0.030 |
Why?
|
| Aortic Valve | 1 | 2019 | 348 | 0.030 |
Why?
|
| Protective Factors | 1 | 2016 | 91 | 0.030 |
Why?
|
| Rabbits | 1 | 2017 | 778 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2017 | 216 | 0.030 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2015 | 89 | 0.030 |
Why?
|
| Potassium | 1 | 2015 | 143 | 0.030 |
Why?
|
| Lumbosacral Region | 1 | 2015 | 56 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2014 | 73 | 0.030 |
Why?
|
| Ultrasonography, Doppler | 1 | 2015 | 118 | 0.030 |
Why?
|
| Equipment Failure | 1 | 2015 | 107 | 0.030 |
Why?
|
| Mass Screening | 1 | 2022 | 1149 | 0.030 |
Why?
|
| Japan | 1 | 2014 | 98 | 0.030 |
Why?
|
| Personnel Selection | 1 | 2015 | 72 | 0.030 |
Why?
|
| Drug Utilization Review | 1 | 2014 | 57 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 198 | 0.030 |
Why?
|
| Treatment Failure | 2 | 2007 | 340 | 0.030 |
Why?
|
| Receptors, Natural Killer Cell | 1 | 2014 | 16 | 0.030 |
Why?
|
| Housing | 1 | 2015 | 130 | 0.030 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2014 | 66 | 0.030 |
Why?
|
| Cell Count | 2 | 2005 | 314 | 0.030 |
Why?
|
| Hypogonadism | 1 | 2014 | 84 | 0.030 |
Why?
|
| Skilled Nursing Facilities | 1 | 2015 | 131 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 2017 | 485 | 0.030 |
Why?
|
| Coronary Disease | 1 | 2016 | 385 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2015 | 306 | 0.030 |
Why?
|
| Health Services Needs and Demand | 1 | 2015 | 264 | 0.030 |
Why?
|
| Glucose Metabolism Disorders | 1 | 2013 | 11 | 0.030 |
Why?
|
| Organ Size | 1 | 2014 | 447 | 0.030 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2012 | 10 | 0.030 |
Why?
|
| Virus Cultivation | 1 | 2012 | 28 | 0.030 |
Why?
|
| Medical Audit | 1 | 2013 | 77 | 0.030 |
Why?
|
| Remission Induction | 1 | 2013 | 272 | 0.030 |
Why?
|
| Health Literacy | 1 | 2015 | 161 | 0.030 |
Why?
|
| Health Services | 1 | 2013 | 99 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2015 | 717 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2014 | 339 | 0.020 |
Why?
|
| Blood Glucose | 2 | 2013 | 2097 | 0.020 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2020 | 1092 | 0.020 |
Why?
|
| Flow Cytometry | 2 | 2005 | 1156 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2014 | 396 | 0.020 |
Why?
|
| Dyslipidemias | 1 | 2013 | 177 | 0.020 |
Why?
|
| Life Style | 1 | 2013 | 460 | 0.020 |
Why?
|
| Blood Chemical Analysis | 1 | 2011 | 96 | 0.020 |
Why?
|
| Hyperlipidemias | 1 | 2011 | 126 | 0.020 |
Why?
|
| Parathyroid Hormone | 1 | 2010 | 106 | 0.020 |
Why?
|
| Natriuretic Agents | 1 | 2009 | 2 | 0.020 |
Why?
|
| Aneurysm | 1 | 2009 | 30 | 0.020 |
Why?
|
| Tracheostomy | 1 | 2011 | 121 | 0.020 |
Why?
|
| Fibroblast Growth Factors | 1 | 2010 | 170 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2013 | 613 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 2011 | 268 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 769 | 0.020 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2009 | 99 | 0.020 |
Why?
|
| Diethylamines | 1 | 2008 | 2 | 0.020 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2009 | 83 | 0.020 |
Why?
|
| Blood Cells | 1 | 2008 | 39 | 0.020 |
Why?
|
| Communication | 1 | 2015 | 846 | 0.020 |
Why?
|
| Chromones | 1 | 2008 | 45 | 0.020 |
Why?
|
| Seasons | 1 | 2011 | 502 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2008 | 148 | 0.020 |
Why?
|
| Smoking | 1 | 2016 | 1501 | 0.020 |
Why?
|
| Fasting | 1 | 2009 | 267 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2009 | 255 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2015 | 1235 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 1838 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2011 | 522 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2008 | 330 | 0.020 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2007 | 22 | 0.020 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2007 | 27 | 0.020 |
Why?
|
| HLA-DP Antigens | 1 | 2007 | 32 | 0.020 |
Why?
|
| HLA-A Antigens | 1 | 2007 | 53 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2009 | 340 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2017 | 1680 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 2012 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2009 | 608 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2010 | 534 | 0.020 |
Why?
|
| Physicians | 1 | 2015 | 865 | 0.020 |
Why?
|
| Heart Ventricles | 1 | 2009 | 781 | 0.010 |
Why?
|
| Phenotype | 1 | 2013 | 3076 | 0.010 |
Why?
|
| Critical Care | 1 | 2009 | 553 | 0.010 |
Why?
|
| Matched-Pair Analysis | 1 | 2003 | 40 | 0.010 |
Why?
|
| Pregnancy | 1 | 2016 | 6402 | 0.010 |
Why?
|
| Wounds and Injuries | 1 | 2010 | 711 | 0.010 |
Why?
|
| Neoplasms | 1 | 2018 | 2470 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2007 | 847 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2004 | 311 | 0.010 |
Why?
|
| Hepatitis C | 1 | 2005 | 238 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 2005 | 601 | 0.010 |
Why?
|
| Stem Cells | 1 | 2005 | 577 | 0.010 |
Why?
|
| Insulin | 1 | 2009 | 2326 | 0.010 |
Why?
|